Revenue CAGR of 30% for FY25-F27. Growth driven by bed ramp-up, specialty mix improvement, higher occupancy. Rich multiples; derating potential if execution falters
Very nice review. Many points well covered. Most importantly CFO/EBIDTA is improving and yes currently stock has valuation. I have invested on your last quarter review so thanks for this.
Request you to share review on Garware Hitech films. Currently stock is under due to tariff.
Amazing !
Thanks
Glad that you liked it. Thanks 🙏🙏🙏. Sure will cover Garware
Very nice review. Many points well covered. Most importantly CFO/EBIDTA is improving and yes currently stock has valuation. I have invested on your last quarter review so thanks for this.
Request you to share review on Garware Hitech films. Currently stock is under due to tariff.
Thanks